Advertisement

Annals of Hematology

, Volume 98, Issue 3, pp 633–645 | Cite as

Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up

  • Bingcheng Liu
  • Ying Wang
  • Chunlin Zhou
  • Hui Wei
  • Dong Lin
  • Wei Li
  • Kaiqi Liu
  • Guangji Zhang
  • Shuning Wei
  • Yan Li
  • Benfa Gong
  • Yuntao Liu
  • Xiaoyuan Gong
  • Yingchang Mi
  • Jianxiang WangEmail author
Original Article

Abstract

The aim of this study is to investigate the efficacy and safety of nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Thirty patients with Ph+ ALL were recruited. Standard induction chemotherapy was given for 4 weeks. Nilotinib was administered beginning on day 15 of induction. After achieving hematologic complete remission (HCR), patients received either seven courses of consolidation or hematopoietic cell transplantation (HCT). Nilotinib was continued 2 years after achieving HCR or before stem cell transplantation conditioning. HCR and molecular complete response (MCR), overall survival (OS), hematologic relapse-free survival (HRFS), molecular relapse-free survival (MRFS), toxicity, and nilotinib levels in the serum and cerebrospinal fluid were evaluated. All patients achieved HCR, and cumulative MCR rate was 83.3%. The median HRFS and OS were 18 and 47.5 months, respectively. Four-year HRFS and OS rates were 54% and 45%, respectively. The median MRFS and 4-year MRFS for the patients with MCR were 19 months and 45%, respectively. The molecular response of patients after induction cycle had no impact on HRFS, MRFS, or OS. The patients who achieved MCR after 3 and 6 months had superior HRFS. The HCT cohort in the first HCR had significantly lower rates of relapse and longer MRFS, HRFS, and OS. Most adverse events were reversible with dose reduction or transient interruption of nilotinib therapy. Only traces of nilotinib were detected in cerebrospinal fluid. Nilotinib combined with cytotoxic chemotherapy was effective and translated to a high HCR and MCR for patients with Ph+ ALL. It should be noted that nilotinib cannot cross the blood–brain barrier.

Keywords

HRFS MRFS Nilotinib OS Ph+ ALL 

Notes

Acknowledgements

The authors thank all the doctors and nurses in the Leukemia Center for their professional assistance.

Funding

This work was supported by the State Key Program of National Natural Science of China (81430004), the Tianjin Clinical Research Center for Blood Diseases (15ZXLCSY00010), the National Natural Science of China (81670159), and the Natural Science Foundation of Tianjin (15JCYBJC25700, 15JCYBJC25000).

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interest.

Research involving human participants

The patients provided the required written informed consent. All procedures were conducted according to the Declaration of Helsinki. The study was approved by the local ethics committee of the Chinese Academy of Medical Sciences and Blood Diseases Hospital (Approval Number: YL2011032201). This trial was registered as ChiCTR-ONC-12002469.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW (2007) Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109(8):3189–3197.  https://doi.org/10.1182/blood-2006-10-051912 CrossRefPubMedGoogle Scholar
  2. 2.
    Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, Fenaux P, Bourhis JH, Fegueux N, Charrin C, Boucheix C, Lheritier V, Esperou H, MacIntyre E, Vernant JP, Fiere D (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood 100(7):2357–2366.  https://doi.org/10.1182/blood-2002-03-0704 CrossRefPubMedGoogle Scholar
  3. 3.
    Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH (2009) Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 113(19):4489–4496.  https://doi.org/10.1182/blood-2009-01-199380 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396–4407.  https://doi.org/10.1182/blood-2003-08-2958 CrossRefPubMedGoogle Scholar
  5. 5.
    Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24(3):460–466.  https://doi.org/10.1200/jco.2005.03.2177 CrossRefPubMedGoogle Scholar
  6. 6.
    Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhauser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Bruck P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG (2006) Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 108(5):1469–1477.  https://doi.org/10.1182/blood-2005-11-4386 CrossRefPubMedGoogle Scholar
  7. 7.
    de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Rea D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lheritier V, Vernant JP, Thomas X, Ifrah N, Dombret H (2007) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109(4):1408–1413.  https://doi.org/10.1182/blood-2006-03-011908 CrossRefPubMedGoogle Scholar
  8. 8.
    Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A (2010) Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 28(22):3644–3652.  https://doi.org/10.1200/jco.2010.28.1287 CrossRefPubMedGoogle Scholar
  9. 9.
    Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J, Del Potro E, Rivas C, Moreno MJ, Tormo M, Martin-Reina V, Sarra J, Parody R, de Oteyza JP, Bureo E, Bernal MT (2010) Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 95(1):87–95.  https://doi.org/10.3324/haematol.2009.011221 CrossRefPubMedGoogle Scholar
  10. 10.
    Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, Fonatsch C, Heyll A, Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99(5):1536–1543CrossRefPubMedGoogle Scholar
  11. 11.
    Lim SN, Joo YD, Lee KH, Kim DY, Lee JH, Lee JH, Chi HS, Yun SC, Lee WS, Lee SM, Park S, Kim I, Sohn SK, Moon JH, Ryoo HM, Bae SH, Hyun MS, Kim MK, Kim HJ, Yang DH, Eom HS, Lee GW, Jung CW, Won JH, Kim H, Lee JH, Shin HJ, Jang DY (2015) Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol 90(11):1013–1020.  https://doi.org/10.1002/ajh.24137 CrossRefPubMedGoogle Scholar
  12. 12.
    Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354(24):2542–2551.  https://doi.org/10.1056/NEJMoa055104 CrossRefPubMedGoogle Scholar
  13. 13.
    Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A, Kim DW, Fan X, Novick S, Giles FJ (2013) Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 27(6):1411–1413.  https://doi.org/10.1038/leu.2012.324 CrossRefPubMedGoogle Scholar
  14. 14.
    Sekimizu M, Yamashita Y, Ueki H, Akita N, Hattori H, Maeda N, Horibe K (2014) Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib. Leuk Lymphoma 55(7):1652–1653.  https://doi.org/10.3109/10428194.2013.842984 CrossRefPubMedGoogle Scholar
  15. 15.
    Farnsworth P, Ward D, Reddy V (2012) Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation. Exp Hematol Oncol 1(1):29.  https://doi.org/10.1186/2162-3619-1-29 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zhang H, Cheng H, Wang Q, Zeng X, Chen Y, Yan J, Sun Y, Zhao X, Li W, Gao C, Gong W, Li B, Zhang R, Nan L, Wu Y, Bao S, Han JD, Zheng H (2015) An advanced fragment analysis-based individualized subtype classification of pediatric acute lymphoblastic leukemia. Sci Rep 5:12435.  https://doi.org/10.1038/srep12435 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655CrossRefPubMedGoogle Scholar
  18. 18.
    Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181.  https://doi.org/10.1016/s1053-4296(03)00031-6 CrossRefPubMedGoogle Scholar
  19. 19.
    Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH (2014) UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123(6):843–850.  https://doi.org/10.1182/blood-2013-09-529008 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H (2010) First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070–2077.  https://doi.org/10.1182/blood-2009-12-261586 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM (2015) Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(23):4158–4164.  https://doi.org/10.1002/cncr.29646 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, Martinelli G, Baccarani M (2011) Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 118(25):6521–6528.  https://doi.org/10.1182/blood-2011-05-351403 CrossRefPubMedGoogle Scholar
  23. 23.
    Rousselot P, Coude MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG (2016) Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 128(6):774–782.  https://doi.org/10.1182/blood-2016-02-700153 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Hoglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112(4):1005–1012.  https://doi.org/10.1182/blood-2008-02-140665 CrossRefPubMedGoogle Scholar
  25. 25.
    Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Douer D, Frankfurt O, Greer JP, Johnson RA, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Rao AV, Shah B, Uy GL, Wang ES, Zelenetz AD, Gregory K, Smith C (2015) Acute Lymphoblastic Leukemia, Version 2.2015. J Natl Compr Cancer Netw 13(10):1240–1279CrossRefGoogle Scholar
  26. 26.
    Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH (2015) Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood 126(6):746–756.  https://doi.org/10.1182/blood-2015-03-636548 CrossRefPubMedGoogle Scholar
  27. 27.
    Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044–1054.  https://doi.org/10.1038/leu.2016.5 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM (2013) Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122(7):1214–1221.  https://doi.org/10.1182/blood-2012-11-466482 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yoon JH, Yhim HY, Kwak JY, Ahn JS, Yang DH, Lee JJ, Kim SJ, Kim JS, Park SJ, Choi CW, Eom HS, Park SK, Choi SY, Kim SH, Kim DW, Lee S (2016) Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol 27(6):1081–1088.  https://doi.org/10.1093/annonc/mdw123 CrossRefPubMedGoogle Scholar
  30. 30.
    Ma L, Hao S, Diong C, Goh YT, Gopalakrishnan S, Ho A, Hwang W, Koh LP, Koh M, Lim ZY, Loh Y, Poon M, Tan LK, Tan P, Linn YC (2015) Pre-transplant achievement of negativity in minimal residual disease and French-American-British L1 morphology predict superior outcome after allogeneic transplant for Philadelphia chromosome positive acute lymphoblastic leukemia: an analysis of Southeast Asian patients. Leuk Lymphoma 56(5):1362–1369.  https://doi.org/10.3109/10428194.2014.956318 CrossRefPubMedGoogle Scholar
  31. 31.
    Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema NA, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B (2009) Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol 27(31):5175–5181.  https://doi.org/10.1200/JCO.2008.21.2514 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S (2015) Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 100(5):653–661.  https://doi.org/10.3324/haematol.2014.118588 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lheritier V, Chevret S, Ifrah N, Dombret H (2015) Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125(24):3711–3719.  https://doi.org/10.1182/blood-2015-02-627935 CrossRefPubMedGoogle Scholar
  34. 34.
    Yuan LI, Wang Y, Lin D, Zhou CL, Liu BC, Wei H, Wei LI, Liu KQ, Wei SN, Gong BF (2015) A study on pharmacokinetics of high dose methotrexate(HD-MTX) in adults with acute lymphoblastic leukemia. Oncology Progress 13:100–104Google Scholar
  35. 35.
    Gaur S, Torabi AR, Corral J (2014) Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor. In Vivo 28(6):1149–1153PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Bingcheng Liu
    • 1
  • Ying Wang
    • 1
  • Chunlin Zhou
    • 1
  • Hui Wei
    • 1
  • Dong Lin
    • 1
  • Wei Li
    • 1
  • Kaiqi Liu
    • 1
  • Guangji Zhang
    • 1
  • Shuning Wei
    • 1
  • Yan Li
    • 1
  • Benfa Gong
    • 1
  • Yuntao Liu
    • 1
  • Xiaoyuan Gong
    • 1
  • Yingchang Mi
    • 1
  • Jianxiang Wang
    • 1
    Email author
  1. 1.Luekemia Center, Institute of Hematology and Blood Disease HospitalChinese Academy of Medical ScienceTianjinChina

Personalised recommendations